Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Dr. Christopher Schaber, President & CEO of Soligenix Inc. talks about the company’s activities.

Video provided courtesy of Thomson Reuters Insider Network

Our Clinical Trials

Learn more >

Partnering with Us

Learn more >